Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Weather
3 NC counties are under alert, including Johnston County.
Program
On FOX50 at 10: Raleigh native & NBA coach is helping teen boys from single-parent households. His foundation & how he is working to bridge a gap
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Antares Pharma
(NQ:
ATRS
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, May 23, 2022
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
-
Bid (Size)
5.590 (55)
Ask (Size)
5.600 (261)
Prev. Close
5.590
Today's Range
N/A - N/A
52wk Range
N/A - N/A
Shares Outstanding
170,579,682
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Looking Into Antares Pharma's Return On Invested Capital
June 08, 2022
Benzinga Pro data, Antares Pharma (NASDAQ:ATRS) reported Q1 sales of $41.56 million. Earnings fell to a loss of $2.32 million, resulting in a 107.1% decrease from last quarter.
Via
Benzinga
ANTARES PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Antares Pharma, Inc. - ATRS
May 05, 2022
From
Kahn Swick & Foti, LLC
Via
Business Wire
Performance
More News
Read More
ANTARES PHARMA INVESTOR ALERT - Kuznicki Law PLLC Investigates Proposed Sale of Antares Pharma, Inc. - ATRS
May 02, 2022
From
Kuznicki Law PLLC
Via
Business Wire
ANTARES PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Antares Pharma, Inc. - ATRS
April 25, 2022
From
Kahn Swick & Foti, LLC
Via
Business Wire
Antares Pharma's Oral Testosterone Treatment Scores FDA Approval
March 29, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 14, 2022
April 14, 2022
Via
Benzinga
Looking Into Antares Pharma Inc's Recent Short Interest
April 14, 2022
Via
Benzinga
Advancements of CAR-T Cell Therapies Importance Grows While Cancer Cases Increasing
April 14, 2022
Via
FinancialNewsMedia
12 Health Care Stocks Moving In Wednesday's Intraday Session
April 13, 2022
Via
Benzinga
Why Is Sierra Oncology (SRRA) Stock Up Today?
April 13, 2022
Via
InvestorPlace
Why Antares Pharma Stock Is Soaring Today
April 13, 2022
Via
Benzinga
Why Is BriaCell (BCTX) Stock Moving Today?
April 13, 2022
Via
InvestorPlace
Why Is Antares Pharma (ATRS) Stock Up Today?
April 13, 2022
Via
InvestorPlace
Benzinga's Daily Brief On Trending Tickers For April 13, 2022: JPMorgan, PayPal, Bed Bath & Beyond And More
April 13, 2022
Via
Benzinga
Biotech Stock Sierra Soars On GSK Buyout As Halozyme Nabs Antares
April 13, 2022
Via
Investor's Business Daily
Futures Rise As Earnings Season Begins
April 13, 2022
Via
Talk Markets
The Daily Biotech Pulse: GlaxoSmithKline And Halozyme Go Shopping, Mylan's Insulin Glargine Recall, Turning Point Shares Lung Cancer Data And More
April 13, 2022
Via
Benzinga
ATRS Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Antares Pharma, Inc. Is Fair to Shareholders
April 13, 2022
From
Halper Sadeh LLP
Via
Business Wire
Morning Brief: Top Stories Dominating Financial Media on Wednesday, April 13
April 13, 2022
Via
Benzinga
Halozyme Buys Antares In $960M Deal To Create One Drug Delivery, Specialty Product Entity
April 13, 2022
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
April 13, 2022
Via
InvestorPlace
The Daily Biotech Pulse: Sanofi-IGM Ink Antibody Drug Collaboration; NeoGenomics Sinks On CEO Departure, Q1 Warning; Decision Day For Akebia
March 29, 2022
Via
Benzinga
The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More
March 27, 2022
Via
Benzinga
Antares Pharma's Return On Capital Employed Overview
March 08, 2022
Via
Benzinga
The Daily Biotech Pulse: NuCana Shelves Biliary Tract Cancer Study, Tricida Data Readout Pushed Back Due to Ukrainian Crisis, Synlogic Names New CFO
March 03, 2022
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.